医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Orthofix Announces Japanese Approval and Market Launch of PHOENIX Minimally Invasive Spinal Fixation System

2016年07月28日 PM09:00
このエントリーをはてなブックマークに追加


 

LEWISVILLE, Texas

Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) of the PHOENIX® Minimally Invasive Spinal (MIS) Fixation System. The introduction of PHOENIX will set the stage for Orthofix to bring more of its innovative spine technologies to this important market in the near future.

“The Japanese approval and full market launch of the PHOENIX MIS fixation system represents an important step towards broadening the availability of our spine fixation products globally by entering the second largest spine market in the world,” said Ray Fujikawa, President of Orthofix Spine Fixation. “We are committed to continuing to work towards securing additional product approvals in order to provide surgeons in Japan with a full range of our spine fixation solutions.”

Estimates by healthcare market research firm GlobalData indicate that by 2020 the spinal fusion market will be $684 million in Japan.

The PHOENIX MIS system enables the percutaneous placement of pedicle screws designed to provide stabilization and correction to assist fusion in patients suffering from degenerative disc disease, spinal stenosis and trauma conditions in the middle and lower back. Featuring a unique implant design for percutaneous and mini open surgical approaches, the PHOENIX MIS system permits a smaller working diameter, thereby reducing the surgical incision.

About Orthofix

Orthofix International N.V. is a diversified, global medical device company focused on improving patients’ lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville, Texas, the Company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely distributed via the Company’s sales representatives, distributors and its subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as the Musculoskeletal Transplant Foundation and the Texas Scottish Rite Hospital for Children. For more information, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries, are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. The forward-looking statements in this release do not constitute guarantees or promises of future performance. Factors that could cause or contribute to such differences may include, but are not limited to the risks described in the “Risk Factors” section of our 2015 Annual Report on Form 10-K, as well as in other reports that we file in the future. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160728005129/en/

CONTACT

Orthofix International N.V.
Investor Relations
Mark Quick,
214-937-2924
markquick@orthofix.com
or
Media
Relations
Denise Landry, 214-937-2529
deniselandry@orthofix.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究